ValiRx launches prostate cancer subsidiary Blue Ribbon Bio
26th Aug 2025 12:35
(Sharecast News) - ValiRx announced a new wholly owned subsidiary Blue Ribbon Bio on Tuesday, to consolidate its prostate cancer assets and accelerate development of its Val201 peptide therapy.
Read moreAmbrose exercises ValiRx oncology option worth up to £16m
20th Jun 2025 13:17
(Sharecast News) - ValiRx confirmed on Friday that Ambrose Healthcare has exercised its option to license the VAL401 oncology asset, in a deal worth up to £16m plus royalties.
Read moreValiRx terminates exclusive negotiations with TheoremRx
3rd Apr 2025 14:58
(Sharecast News) - ValiRx announced the immediate termination of its letter of intent with TheoremRx on Thursday, ending exclusive negotiations originally set to run until 31 May.
Read moreValiRx's Inaphaea inks deal with UK-based Screenin3D
3rd Feb 2025 12:20
(Sharecast News) - ValiRx announced on Monday that its wholly-owned subsidiary Inaphaea BioLabs has signed an evaluation and commercial use agreement with UK-based Screenin3D.
Read moreValiRx enters evaluation and option deal with Canada's Altus
29th Jan 2025 11:13
(Sharecast News) - ValiRx announced on Wednesday that it has entered into an evaluation and option agreement with Canada-based Altus Formulation to assess the potential of Altus' SmartCelle drug delivery technology and novel anti-inflammatory compounds for cancer treatment.
Read moreValiRx further extends letter of intent with TheoremRx
31st Dec 2024 11:07
(Sharecast News) - ValiRx, a life science company specialising in early-stage cancer therapeutics and women's health, announced a further amendment to its letter of intent with TheoremRx regarding the proposed sub-license of VAL201 on Tuesday.
Read moreValiRx shares tank on £1.6m fundraising plan to support R&D
9th Dec 2024 09:43
(Sharecast News) - Shares in life sciences firm ValiRx plummeted on Monday after the AIM-listed firm announced plans to raise £1.57m to increase its R&D efforts as it continues the development of breast cancer treatment CytoLytix.
Read moreValiRx subsidiary makes first sale
18th Nov 2024 14:04
(Sharecast News) - ValiRx, a life science company focussed on early-stage cancer therapeutics and women's health, announced the first sale from its wholly-owned subsidiary Inaphaea BioLabs on Monday.
Read moreValiRx losses narrow in first half
27th Sep 2024 11:33
(Sharecast News) - ValiRx, a life science company focussed on cancer therapeutic development, reported a total comprehensive loss of £0.97m for the six months ended 30 June on Friday, narrowing from a loss of £1.04m in the same period last year.
Read moreValiRx pulls out of University of Barcelona collaboration
26th Sep 2024 12:05
(Sharecast News) - ValiRx said in an update on Thursday that it has concluded its evaluation project with the University of Barcelona, focussed on early-stage cancer therapeutics targeting the 'KRAS2' series of drug candidates.
Read moreValiRx subsidiary inks agreement with research firm Xenopat
18th Sep 2024 12:48
(Sharecast News) - London-based life science company ValiRx has announced that its wholly-owned subsidiary, Inaphaea BioLabs, has entered into an evaluation and commercial use agreement with Spanish contract research organisation Xenopat.
Read moreValiRx inks deal with Dundee Drug Discovery Unit
12th Feb 2024 12:59
(Sharecast News) - ValiRx announced the signing of a significant agreement with the University of Dundee and its Drug Discovery Unit (DDU) on Monday.
Read moreValiRx enters option deal with Ambrose Healthcare
5th Dec 2023 15:08
(Sharecast News) - Cancer therapeutics-focussed life science company ValiRx announced on Tuesday that its subsidiary ValiSeek has entered into an exclusive option agreement with Ambrose Healthcare, a private UK-based pharmaceutical company.
Read moreValiRx enters partnership with StingRay Bio
10th Nov 2023 10:32
(Sharecast News) - Life science company ValiRx announced a new partnership with StingRay Bio on Friday, aiming to explore a promising lead series of drug candidates designed for oncology applications.
Read moreValiRx shares jump as H1 losses shrink
24th Aug 2023 09:59
(Sharecast News) - Shares in ValiRx jumped nearly on Thursday after the biotech posted results for its first half, in which losses per share shrunk by a third.
Read more